Omnicell (NASDAQ:OMCL) Share Price Passes Above 200-Day Moving Average - What's Next?

Key Points

• Omnicell's share price has recently crossed above its 200-day moving average, reaching a high of $32.05 before closing at $31.00.
• Analysts have mixed opinions on Omnicell; Wall Street Zen downgraded the stock from a "strong-buy" to a "buy," while Wells Fargo raised its price target to $40.00.
• The company reported earnings of $0.45 per share for the last quarter, exceeding estimates, with projected fiscal year 2025 earnings guidance of 1.400-1.650 EPS.

Omnicell, Inc. (NASDAQ:OMCL - Get Free Report)'s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $30.76 and traded as high as $32.05. Omnicell shares last traded at $31.00, with a volume of 570,525 shares traded.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on OMCL. Wall Street Zen lowered Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Wells Fargo & Company boosted their target price on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research note on Monday, July 21st. Finally, Piper Sandler lowered their target price on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, August 11th. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $46.71.

Omnicell Stock Down 2.0%

The firm has a market cap of $1.42 billion, a price-to-earnings ratio of 62.00, a P/E/G ratio of 6.91 and a beta of 0.82. The firm's 50 day moving average price is $31.11 and its two-hundred day moving average price is $30.76. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.30 by $0.15. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. The business had revenue of $290.56 million during the quarter, compared to the consensus estimate of $275.57 million. During the same quarter in the prior year, the firm earned $0.51 earnings per share. The business's quarterly revenue was up 5.0% compared to the same quarter last year. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, sell-side analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Insider Transactions at Omnicell

In related news, EVP Corey J. Manley sold 3,880 shares of the stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $33.25, for a total transaction of $129,010.00. Following the completion of the transaction, the executive vice president directly owned 110,653 shares of the company's stock, valued at $3,679,212.25. This represents a 3.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 2.52% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Thrivent Financial for Lutherans lifted its position in shares of Omnicell by 1.2% during the 2nd quarter. Thrivent Financial for Lutherans now owns 34,445 shares of the company's stock valued at $1,013,000 after acquiring an additional 424 shares during the period. Liontrust Investment Partners LLP lifted its position in shares of Omnicell by 81.2% during the 2nd quarter. Liontrust Investment Partners LLP now owns 318,284 shares of the company's stock valued at $9,358,000 after acquiring an additional 142,629 shares during the period. Public Sector Pension Investment Board lifted its position in shares of Omnicell by 8.7% during the 2nd quarter. Public Sector Pension Investment Board now owns 159,658 shares of the company's stock valued at $4,694,000 after acquiring an additional 12,742 shares during the period. Headlands Technologies LLC lifted its position in shares of Omnicell by 1,865.0% during the 2nd quarter. Headlands Technologies LLC now owns 18,137 shares of the company's stock valued at $533,000 after acquiring an additional 17,214 shares during the period. Finally, CANADA LIFE ASSURANCE Co lifted its position in shares of Omnicell by 3.2% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 53,233 shares of the company's stock valued at $1,566,000 after acquiring an additional 1,638 shares during the period. 97.70% of the stock is owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.